Antemortem CSF A β 42/A β 40 ratio predicts Alzheimer's disease pathology better than A β 42 in rapidly progressive dementias

The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis: A review

(2018) Oskar Hansson et al.   Alzheimers & Dementia

NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease

(2018) Clifford R. Jack et al.   Alzheimers & Dementia

Cerebrospinal Fluid Biomarkers for Early and Differential Alzheimer’s Disease Diagnosis

(2018) Maria Bjerke et al.   JOURNAL OF ALZHEIMERS DISEASE

A Specific Reduction in Aβ1−42 vs. a Universal Loss of Aβ Peptides in CSF Differentiates Alzheimer's Disease From Meningitis and Multiple Sclerosis

(2018) Philipp Spitzer et al.   Frontiers in Aging Neuroscience

Additional Use of Aβ42/Aβ40 Ratio with Cerebrospinal Fluid Biomarkers P-Tau and Aβ42 Increases the Level of Evidence of Alzheimer's Disease Pathophysiological Process in Routine Practice

(2018) Mathilde Sauvée et al.   JOURNAL OF ALZHEIMERS DISEASE

The Cerebrospinal Fluid Aβ1–42/Aβ1–40 Ratio Improves Concordance with Amyloid-PET for Diagnosing Alzheimer’s Disease in a Clinical Setting

(2017) Ellis Niemantsverdriet et al.   JOURNAL OF ALZHEIMERS DISEASE

Clinical validity of cerebrospinal fluid Aβ42, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework

(2017) Niklas Mattsson et al.   NEUROBIOLOGY OF AGING

Concordance Between Different Amyloid Immunoassays and Visual Amyloid Positron Emission Tomographic Assessment

(2017) Shorena Janelidze et al.   JAMA Neurology

Pittsburgh compound B imaging and cerebrospinal fluid amyloid-β in a multicentre European memory clinic study

(2016) Antoine Leuzy et al.   BRAIN

Cerebrospinal Fluid Aβ42/40 Corresponds Better than Aβ42 to Amyloid PET in Alzheimer’s Disease

(2016) Piotr Lewczuk et al.   JOURNAL OF ALZHEIMERS DISEASE

Reference measurement procedure for CSF amyloid beta (Aβ)1-42and the CSF Aβ1-42/Aβ1-40ratio - a cross-validation study against amyloid PET

(2016) Josef Pannee et al.   JOURNAL OF NEUROCHEMISTRY

Alzheimer's disease

(2016) Philip Scheltens et al.   LANCET

CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis

(2016) Bob Olsson et al.   LANCET NEUROLOGY

Cerebrospinal fluid biomarkers in Alzheimer's and Parkinson's diseases-From pathophysiology to clinical practice

(2016) Kaj Blennow et al.   MOVEMENT DISORDERS

A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers

(2016) Clifford R. Jack et al.   NEUROLOGY

CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios: better diagnostic markers of Alzheimer disease

(2016) Shorena Janelidze et al.   Annals of Clinical and Translational Neurology

Amyloid biomarkers in Alzheimer's disease

(2015) Kaj Blennow et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Cerebrospinal fluid amyloid-β 42/40 ratio in clinical setting of memory centers: a multicentric study

(2015) Julien Dumurgier et al.   Alzheimers Research & Therapy

Cerebrospinal Fluid Aβ40 Improves the Interpretation of Aβ42 Concentration for Diagnosing Alzheimer’s Disease

(2015) Aline Dorey et al.   Frontiers in Neurology

Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria

(2014) Bruno Dubois et al.   LANCET NEUROLOGY

Consensus classification of human prion disease histotypes allows reliable identification of molecular subtypes: an inter-rater study among surveillance centres in Europe and USA

(2012) Piero Parchi et al.   ACTA NEUROPATHOLOGICA

National Institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach

(2011) Thomas J. Montine et al.   ACTA NEUROPATHOLOGICA

Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

(2011) Reisa A. Sperling et al.   Alzheimers & Dementia

The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease

(2011) Guy M. McKhann et al.   Alzheimers & Dementia

Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease

(2010) C. R. Jack et al.   BRAIN

Assessment of β-amyloid deposits in human brain: a study of the BrainNet Europe Consortium

(2009) Irina Alafuzoff et al.   ACTA NEUROPATHOLOGICA

Incidence and spectrum of sporadic Creutzfeldt–Jakob disease variants with mixed phenotype and co-occurrence of PrPSc types: an updated classification

(2009) Piero Parchi et al.   ACTA NEUROPATHOLOGICA

Cerebrospinal Fluid β-Amyloid 42 and Tau Proteins as Biomarkers of Alzheimer-Type Pathologic Changes in the Brain

(2009) Tero Tapiola et al.   ARCHIVES OF NEUROLOGY

Mixed Brain Pathologies in Dementia: The BrainNet Europe Consortium Experience

(2008) Gabor G. Kovacs et al.   DEMENTIA AND GERIATRIC COGNITIVE DISORDERS